Monthly Archives: February 2012

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this monotherapy study 66% of patients who received the highest dose achieved … Continue reading →

The Portuguese Parliament on Thursday by a majority vote approved a bill that legalizes abortions during the first 10 weeks of pregnancy, Reuters/Washington Post reports (Reuters/Washington Post, 3/9). Abortion is illegal in Portugal except when necessary to protect the life … Continue reading →

Hispanic women with hypertension and coronary artery disease respond better to drug regimens aimed at controlling high blood pressure than non-Hispanic white women, University of Florida researchers report. A UF study described in the current issue of the Journal of … Continue reading →

The result of a ballot initiative to uphold or reject a South Dakota law (HB 1215) banning abortions except to save a woman’s life will “set the tone” for the outcome of similar measures being considered in nearly 12 states, … Continue reading →

The female hormone estrogen is considered to be a quasi-fuel for developing breast cancer. Now Virginia Tech College of Engineering researchers will use a $1.56 million grant from the National Institutes of Health’s National Cancer Institute to inhibit estrogen and … Continue reading →

Grappling with the risks and benefits of hormone replacement therapy (HRT) is nothing new for postmenopausal women. Researchers have now added more fuel to the fire, with evidence that HRT could play a role in incontinence. “Our main finding, which … Continue reading →